| Titel: | Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre Phase I/II study of the East German Hematology and Oncology Study Group (OSHO) |
| Kurzbezeichnung: | RAS-AZIC |
| Studienleitung: | PD Dr. med., Haifa Kathrin Al-Ali Tel: +49 (0)345 557-4959 Fax: +49 (0)345 557-2950 E-Mail: haifa.al-ali@uk-halle.de |
| Rekrutierungszeitraum: | Start 31.08.2012 |
Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
Juliane Grimm, Donjete Simnica, Nadja Jäkel, Lisa Paschold, Edith Willscher, Susann Schulze, Christine Dierks, Haifa Kathrin Al-Ali, Mascha Binder
♦ Blood Cancer Journal (2022)12:19
♦ https://doi.org/10.1038/s41408-022-00615-7